A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Clinical trial NCT04980222 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04980222
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-22
- Primary completion
- 2024-09-24
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.